Inner-City Availability of Preservative-Containing Albuterol

Abstract

Benzalkonium chloride (BAC) added to nebulized albuterol may induce bronchospasm. The objective of this study was to determine the availability of BAC-containing nebulized albuterol in the Bronx, New York pharmacies. A cross-sectional telephone survey of pharmacies was conducted. Overall, 158 (80%) pharmacies participated in the survey; 133 (84%) carried BAC-containing albuterol; 25 (16%) dispensed BAC-containing albuterol solution when presented with a prescription written for generic albuterol. Only 14 (9%) pharmacists had seen a prescription for nebulized albuterol where a physician specified “without BAC.” Despite availability of BAC-free albuterol, pharmacies in the Bronx still carried and dispensed BAC-containing product.

Get full access to this article

View all access options for this article.

References

Delgado A , Chou KJ , Silver EJ , et al. Nebulizers vs metered-dose inhalers with spacers for bronchodilator therapy to treat wheezing in children aged 2 to 24 months in a pediatric emergency department. Arch Pediatr Adolesc Med. 2003;157(1):76-80.

Ploin D , Chapuis FR , Stamm D , et al. High-dose albuterol by metered-dose inhaler plus a spacer device versus nebulization in preschool children with recurrent wheezing: a double-blind, randomized equivalence trial. Pediatrics. 2000;106(2 Pt 1):311-317.

Beasley R , Fishwick D , Miles JF , et al. Preservatives in nebulizer solutions: risks without benefit. Pharmacotherapy. 1998;18(1):130-139.

Crain EF , Weiss KB , Bijur PE , et al. An estimate of the prevalence of asthma and wheezing among inner-city children. Pediatrics. 1994;94(3):356-362.

Available at: YellowPages.com.

Beasley CRW , Rafferty P , Holgate ST . Bronchoconstrictor properties of preservatives in ipratropium bromide (Atrovent) nebulizer solution. BMJ. 1987;294:1197-1198.

Zhang YG , Wright WJ , Tam WK , et al. Effects of inhaled preservatives on asthmatic subjects, II: benzalkonium chloride. Am Rev Respir Dis. 1990;141:1405-1408.

Miszkiel KA , Beasley R , Rafferty P , et al. The contribution of histamine release to bronchoconstriction in asthma. Br J Clin Pharmacol. 1988;25:157-163.

O’Callaghan CO , Milner AD , Swarbrick A . Paradoxical determination in lung function after nebulised albuterol in wheezy infants. Lancet. 1986;2:1424-1425.

10.

Prendiville A , Green S , Silverman M . Paradoxical response to nebulizer albuterol in wheezy infants, assessed by partial expiratory flow-volume curves. Thorax. 1987;42:86-91.

11.

Boucher M , Roy MT , Henderson J . Possible associations of benzalkonium chloride in nebulizer solutions with respiratory arrest. Ann Pharmacother. 1992;26:772-773.

12.

Menendez R , Lowe R , Kersey J . Benzalkonium chloride and bronchoconstriction. J Allergy Clin Immunol. 1989;84:272-274.

13.

Asmus MJ , Barros MD , Liang J , et al. Pulmonary function response to EDTA, an additive in nebulized bronchodilators. J Allergy Clin Immunol. 2001;107:68-72.

14.

Kwong T , Flatt A , Crane J , Beasley R . The effect of benzalkonium chloride on the bronchodilator response to albuterol nebuliser solution. N Z Med J. 1990;103:457.

15.

Department of Health and Human Services . Food and Drug Administration. 21 CFR Part 200. Sterility Requirement for Aqueous-Based Drug Products for Oral Inhalation. Federal Register. Vol. 65, No. 103; May 26, 2000.

16.

Beasley R , Burgess C , Holt S . Call for worldwide withdrawal of benzalkonium chloride from nebulizer solutions. J Allergy Clin Immunol. 2001;107:222-223.